Nordisk issues voluntary recall of GlucaGen HypoKits

Novo Nordisk (NYSE:NVO) issued a voluntary recall of 6 batches of its GlucaGen HypoKits in the U.S., after reports of detached needles in the syringes. The company initiated the recall following 2 customer complaints, 1 from the UK and 1 from Portugal, according to Novo Nordisk.

The recall comes just days after the company announced the retirement of president & CEO Lars Sorenson.

The GlucaGen HypoKit is used to treat hypoglycemia in patients with diabetes who are also taking insulin. Hypoglycemia, or low blood sugar, can prove fatal if left untreated. The devices don’t work as prescribed if the needle from the syringe is detached.

The Danish diabetes giant estimates that 0.006% of needles could be detached among the 6 batches, which accounts for 4 pens out of 71,215. The company is collaborating with the FDA to recall the affected devices, while reaching out to users by mail and over the phone to warn them.

Novo reports that there is no record of the recalled batches causing any harm.

Its stock was trading at $44.40 apiece today in mid-afternoon activity, down 3.4%.

The post Nordisk issues voluntary recall of GlucaGen HypoKits appeared first on MassDevice.

from MassDevice http://ift.tt/2cfJRa4